Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic.

Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BD, Grijsen ML, Prins JM, Schuitemaker H.

J Virol. 2011 Jul;85(14):7236-45. doi: 10.1128/JVI.00196-11. Epub 2011 May 11.

2.

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.

Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H.

J Virol. 2007 Aug;81(16):8533-42. Epub 2007 May 23.

3.

Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.

Hoffenberg S, Powell R, Carpov A, Wagner D, Wilson A, Kosakovsky Pond S, Lindsay R, Arendt H, Destefano J, Phogat S, Poignard P, Fling SP, Simek M, Labranche C, Montefiori D, Wrin T, Phung P, Burton D, Koff W, King CR, Parks CL, Caulfield MJ.

J Virol. 2013 May;87(10):5372-83. doi: 10.1128/JVI.02827-12. Epub 2013 Mar 6.

4.

Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.

Thenin S, Roch E, Samleerat T, Moreau T, Chaillon A, Moreau A, Barin F, Braibant M.

J Gen Virol. 2012 Jul;93(Pt 7):1495-505. doi: 10.1099/vir.0.042614-0. Epub 2012 Apr 4.

PMID:
22492917
5.

Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups.

Braibant M, Gong EY, Plantier JC, Moreau T, Alessandri E, Simon F, Barin F.

AIDS. 2013 May 15;27(8):1239-44. doi: 10.1097/QAD.0b013e32835ecb42.

PMID:
23343910
6.

Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic.

Bouvin-Pley M, Morgand M, Moreau A, Jestin P, Simonnet C, Tran L, Goujard C, Meyer L, Barin F, Braibant M.

PLoS Pathog. 2013;9(7):e1003477. doi: 10.1371/journal.ppat.1003477. Epub 2013 Jul 4.

7.

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.

Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker LG, Hoelscher M, Maboko L, Makhema J, Robb ML, Abdool Karim S, Abdool Karim Q, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, Williamson C.

PLoS Pathog. 2016 Jul 19;12(7):e1005742. doi: 10.1371/journal.ppat.1005742. eCollection 2016 Jul. Erratum in: PLoS Pathog. 2017 Sep 25;13(9):e1006641.

8.

Association between HIV-1 coreceptor usage and resistance to broadly neutralizing antibodies.

Pfeifer N, Walter H, Lengauer T.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):107-12. doi: 10.1097/QAI.0000000000000283.

9.

HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype.

Mabuka J, Goo L, Omenda MM, Nduati R, Overbaugh J.

AIDS. 2013 Jun 19;27(10):1535-44. doi: 10.1097/QAD.0b013e32835faba5.

10.

Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H.

J Gen Virol. 2010 May;91(Pt 5):1354-64. doi: 10.1099/vir.0.017319-0. Epub 2010 Jan 6.

PMID:
20053822
11.

Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes.

Russell ES, Ojeda S, Fouda GG, Meshnick SR, Montefiori D, Permar SR, Swanstrom R.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):511-5. doi: 10.1089/AID.2012.0197. Epub 2013 Jan 18.

12.

HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.

Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J.

AIDS. 2007 Mar 30;21(6):693-702.

PMID:
17413690
13.

Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.

Gombos RB, Kolodkin-Gal D, Eslamizar L, Owuor JO, Mazzola E, Gonzalez AM, Korioth-Schmitz B, Gelman RS, Montefiori DC, Haynes BF, Schmitz JE.

J Virol. 2015 Aug;89(15):7813-28. doi: 10.1128/JVI.00783-15. Epub 2015 May 20.

14.

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, van Nuenen AC, Schuitemaker H.

Virology. 2009 Aug 1;390(2):348-55. doi: 10.1016/j.virol.2009.05.028. Epub 2009 Jun 17.

15.

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR.

PLoS Pathog. 2010 Aug 5;6(8):e1001028. doi: 10.1371/journal.ppat.1001028.

16.

Single-chain Fv-based anti-HIV proteins: potential and limitations.

West AP Jr, Galimidi RP, Gnanapragasam PN, Bjorkman PJ.

J Virol. 2012 Jan;86(1):195-202. doi: 10.1128/JVI.05848-11. Epub 2011 Oct 19.

17.

Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

Doores KJ, Burton DR.

J Virol. 2010 Oct;84(20):10510-21. doi: 10.1128/JVI.00552-10. Epub 2010 Aug 4.

18.

Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.

van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw-Klein M, Verwer N, Schuitemaker H.

J Virol. 2011 Jul;85(14):6986-95. doi: 10.1128/JVI.00268-11. Epub 2011 May 18.

19.

Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.

Rademeyer C, Moore PL, Taylor N, Martin DP, Choge IA, Gray ES, Sheppard HW, Gray C, Morris L, Williamson C; HIVNET 028 study team.

Virology. 2007 Nov 10;368(1):172-81. Epub 2007 Jul 16.

Supplemental Content

Support Center